Akhila Kosaraju, MD

In the final episode of the short series, Akhila Kosaraju, MD, talks about changing the development paradigm and moving away from reengineering molecules of existing antibiotic classes and towards creating new ones.

In the second episode of this short series, Akhila Kosaraju, MD, talks about how Phare Bio and Basilea Pharmaceuticals are partnering to develop antimicrobials taking them from AI molecules to clinical trials.

Akhila Kosaraju, MD, provides insights around how AI is moving towards an accelerated pace of antimicrobial development in hopes of getting molecules into clinical trials and approved much faster than the current paradigm.

Akhila Kosaraju, MD, addresses overcoming key challenges in antibiotic development using AI, a nonprofit model, and supportive policies.